Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous vs Intravenous ALXN1210 in Healthy Subjects
NCT05288829Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 200 and Absolute Bioavailability of ALXN1210 SC at Day 150. Started Aug 2016; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05288829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288829.